|[March 20, 2017]
Selexis Announces Launch of Novel Cell Selection Platform Designed to Help Advance Difficult-to-Express Protein Therapeutics to the Clinic
SA, a pioneering life sciences company and a global leader in
mammalian (suspension-adapted CHO-K1) cell line generation, announced
today the launch of a novel selection method to screen and pick cells
with optimal expression levels. Selexis developed SUREselect™ to
help partners advance difficult-to-express (DTE) proteins to the clinic.
The selection of high-producing and stable mammalian cell lines can
represent a bottleneck in process development for the production of
biopharmaceuticals, particularly for difficult-to-express and cytotoxic
proteins. As part of its ongoing commitment to develop expression
solutions for challenging proteins, Selexis has developed SUREselect,
a novel and patented selection method based on the co-expression of a
vitamin B5 transporter in combination with the transfected therapeutic
gene(s) and which exploits CHO cell dependency on this vitamin for
energy production. SUREselect strengthens the commonly used
antibiotic selection and gives growth advantage to cells' subpopulation
with the best-fitted metabolic responses to DTE production.
Using SUREselect, Selexis has been able to increase production
levels four-fold for a range of difficult-to-express proteins, including
Fc-fusion proteins and cytokines that were cytotoxic to CHO cell lines.
This new development of the SUREtechnology Platform™ provides a
unique solution for difficult-to-express proteins, which can rescue
programs that otherwise would not be viable for clinical development
based on production requirements.
"There continues to be a demand for novel methods for the selection of
cell lines stably expressing therapeutic proteins at clinical and
commercial levels," said Igor Fisch, PhD, Selexis chairman and chief
executive officer. "SUREselect offers our partners an entirely
new way for selecting production clones and gives them unique solutions
for programs that otherwise would be terminated due to non-clinically
and commercially viable production levels. By achieving high titers of
the expressed product, SUREselect can also reduce the overall
costs of goods."
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in
mammalian (suspension-adapted CHO-K1) cell line generation, providing
unparalleled proprietary technology and the highly specialized expertise
that is necessary to translate scientific innovation into life-saving
medicines for patients. Selexis' SUREtechnology Platform™
facilitates the rapid, stable, and cost-effective production of
virtually any recombinant protein and provides seamless integration of
the bioproduction continuum, spanning discovery to commercialization.
With more than 95 partners worldwide, nearly 80 drug products in
clinical manufacturing and two commercial products utilizing its cell
lines, Selexis has a history of empowering scientists and
biopharmaceutical companies around the world to realize the full
potential of their research. More information is available at www.selexis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170320005329/en/
[ Back To TMCnet.com's Homepage ]